Living Evidence Portfolio

Mahmood Ahmad · Tahir Heart Institute · 57 living systematic reviews · Every number traces to its source

57
Living MAs
12
Specialties
766
Trials
7
Dose-Response
4
NMA
Cardiology

ATTR-CM Therapies Ultra-Precision

15 trials · 13,661 lines · HR
Neurology

Anti-Amyloid in Alzheimers

14 trials · 14,499 lines · RR
DOSE-RESPONSE
NMA

Antiplatelet De-escalation NMA

14 trials · 14,252 lines · HR
NMA
Cardiology

Bempedoic Acid Ultra-Precision

16 trials · 13,805 lines · HR
Dermatology

Bimekizumab Psoriasis

14 trials · 14,545 lines · RR
DOSE-RESPONSE
Interventional

CT-FFR Guided Strategy

12 trials · 14,437 lines · RR
Cardiology

Catheter Ablation for AF Ultra-Precision

13 trials · 13,651 lines · HR
Cardiology

Colchicine Anti-Inflammatory CVD

14 trials · 11,108 lines · OR
Interventional

Conduction System Pacing

14 trials · 14,448 lines · RR
Interventional

Coronary IVL (Shockwave)

14 trials · 14,463 lines · RR
Cardiology

DOACs for Cancer-Associated VTE Ultra-Precision

13 trials · 13,651 lines · HR
Cardiology

Dapagliflozin in Acute HF

12 trials · 14,191 lines · HR
Peripheral Vascular

Drug-Coated Balloons in PAD

19 trials · 14,472 lines · RR
Pulmonology

Dupilumab in COPD

9 trials · 14,184 lines · RR
Cardiology

Empagliflozin in Acute MI

10 trials · 14,439 lines · HR
Oncology

Enfortumab Vedotin UC

8 trials · 14,172 lines · HR
Cardiology

Finerenone Ultra-Precision

12 trials · 14,525 lines · AUTO
Cardiometabolic

GLP-1 RA CVOT Ultra-Precision

50 trials · 14,902 lines · OR
NMA

HFrEF Quadruple Therapy NMA

11 trials · 14,240 lines · HR
NMA
Cardiology

IV Iron in Heart Failure Ultra-Precision

13 trials · 13,650 lines · HR
Cardiology

Icosapent Ethyl (EPA) CV

11 trials · 14,448 lines · HR
Cardiology

Inclisiran (siRNA PCSK9)

14 trials · 14,446 lines · RR
Cardiometabolic

Incretin Therapies in HFpEF Ultra-Precision

12 trials · 13,651 lines · HR
Cardiology

Intensive BP Precision

27 trials · 13,533 lines · AUTO
Nephrology

Iptacopan (Factor B Inhibitor)

8 trials · 14,163 lines · RR
Oncology

KRAS G12C Inhibitors NSCLC

14 trials · 14,203 lines · HR
Interventional

Leadless Pacing

17 trials · 14,475 lines · RR
Cardiology

Mavacamten for Obstructive HCM Ultra-Precision

12 trials · 13,645 lines · AUTO
NMA

Obesity Pharmacotherapy NMA

17 trials · 14,576 lines · RR
DOSE-RESPONSE NMA
Cardiology

Omecamtiv Mecarbil

13 trials · 14,448 lines · HR
Cardiology

Omega-3 & Icosapent Ethyl CVD Prevention

15 trials · 13,749 lines · AUTO
Cardiometabolic

Orforglipron (Oral GLP-1)

20 trials · 14,476 lines · RR
Oncology

Osimertinib in EGFR+ NSCLC

14 trials · 14,466 lines · HR
NMA

PAH Therapies NMA

14 trials · 14,259 lines · HR
NMA
Cardiology

PCSK9 Inhibitor Precision

8 trials · 13,605 lines · AUTO
Interventional

PFA in Atrial Fibrillation

11 trials · 14,432 lines · RR
Oncology

Pembrolizumab Adj Melanoma

7 trials · 14,167 lines · HR
Nephrology

Potassium Binders (RAASi Enablement)

17 trials · 14,524 lines · RR
DOSE-RESPONSE
Cardiology

Renal Denervation for HTN Ultra-Precision

12 trials · 13,668 lines · MD
Hepatology

Resmetirom for MASH

11 trials · 14,474 lines · RR
DOSE-RESPONSE
Cardiology

Rivaroxaban Vascular Protection Ultra-Precision

13 trials · 13,652 lines · HR
Nephrology

SGLT2 Inhibitors in CKD Ultra-Precision

10 trials · 13,641 lines · HR
Cardiology

SGLT2-HF Ultra-Precision

15 trials · 11,192 lines · OR
Oncology

Sacituzumab Govitecan Breast

12 trials · 14,193 lines · HR
Cardiology

Sacubitril/Valsartan (ARNI) in HF Ultra-Precision

12 trials · 13,651 lines · HR
Nephrology

Semaglutide in CKD

7 trials · 14,432 lines · HR
Cardiometabolic

Semaglutide in HFpEF

10 trials · 14,437 lines · RR
Cardiology

Sotagliflozin (Dual SGLT1/2i)

11 trials · 14,450 lines · HR
Pulm Vascular

Sotatercept in PAH

12 trials · 14,450 lines · HR
Nephrology

Sparsentan in IgA Nephropathy

8 trials · 14,163 lines · RR
Oncology

T-DXd in Breast Cancer

14 trials · 14,465 lines · HR
Pulmonology

Tezepelumab in Severe Asthma

13 trials · 14,546 lines · RR
DOSE-RESPONSE
Cardiology

Ticagrelor Monotherapy Post-PCI

13 trials · 14,465 lines · HR
Cardiometabolic

Tirzepatide CV/Obesity

14 trials · 14,489 lines · RR
DOSE-RESPONSE
Interventional

Tricuspid TEER

8 trials · 14,438 lines · RR
Cardiology

Vericiguat in Heart Failure

11 trials · 14,434 lines · HR
Interventional

Watchman FLX vs Amulet LAAO

12 trials · 14,462 lines · RR